Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817524 | 1.00 | FAAH (0.33) | FAAHMAPTKMT2ALMNATSHR | |
| SCHEMBL6658955 | 1.00 | FAAH (0.33) | FAAHMAPTKMT2ALMNATSHR | |
| SCHEMBL4814201 | 1.00 | FAAH (0.33) | FAAHMAPTKMT2ALMNATSHR | |
| SCHEMBL29259719 | 0.91 | — | — | |
| SCHEMBL11553771 | 0.80 | MAPT (0.44) | FAAHMAPTKMT2ALMNATSHR | |
| SCHEMBL19816441 | 0.79 | MAPT (0.37) | MAPTKMT2ALMNATSHRNFKB1 | |
| SCHEMBL3992011 | 0.77 | KMT2A (0.56) | MAPTKMT2ATSHR | |
| SCHEMBL3987319 | 0.77 | KMT2A (0.56) | MAPTKMT2ATSHR | |
| SCHEMBL3993682 | 0.77 | KMT2A (0.56) | MAPTKMT2ATSHR | |
| SCHEMBL3987265 | 0.77 | KMT2A (0.56) | MAPTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371779-B2 | Synergistic compositions of N-acylhomoserine lactones and 4-quinolones | THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) | 2008-05-13 | — | — | US | claimed |
| US-20050014751-A1 | Use of n-acyl homoserine lactones for the treatment of insulitis | THE UNIVERSITY OF NOTTINGHAM (GB) | 2005-01-20 | — | — | US | claimed |
| US-20040259942-A1 | Modulation of stat activity | SHAW PETER (GB) | 2004-12-23 | — | — | US | claimed |
| EP-1404315-B1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | UNIV NOTTINGHAM (GB) | 2004-11-03 | — | — | EP | claimed |
| US-20040198978-A1 | Synergistic compositions of n-acylhomoserine lactones and 4-quinolones | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2004-10-07 | — | — | US | claimed |
| EP-1427406-A2 | MODULATION OF STAT ACTIVITY | University of Nottingham (GB) | 2004-06-16 | — | — | EP | claimed |
| EP-1425274-A1 | USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2004-06-09 | — | — | EP | claimed |
| EP-1404315-A1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2004-04-07 | — | — | EP | claimed |
| US-20030171371-A1 | Immunosuppressant n-acyles homoserine lactones | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-09-11 | — | — | US | claimed |
| WO-2003026641-A2 | MODULATION OF STAT ACTIVITY | UNIVERSITY OF NOTTINGHAM (GB) | 2003-04-03 | — | — | WO | claimed |
| WO-2003022828-A1 | USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-03-20 | — | — | WO | claimed |
| WO-2003004017-A1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-01-16 | — | — | WO | claimed |
| EP-1268459-A1 | IMMUNOSUPPRESSANT N-ACYL HOMOSERINE LACTONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-01-02 | — | — | EP | claimed |
| WO-2001074801-A1 | IMMUNOSUPPRESSANT N-ACYLES HOMOSERINE LACTONES | UNIVERSITY OF NOTTINGHAM (GB) | 2001-10-11 | — | — | WO | claimed |
| US-7371779-B2 | Synergistic compositions of N-acylhomoserine lactones and 4-quinolones | THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) | 2008-05-13 | — | — | US | disclosed |
| US-20050014751-A1 | Use of n-acyl homoserine lactones for the treatment of insulitis | THE UNIVERSITY OF NOTTINGHAM (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20040259942-A1 | Modulation of stat activity | SHAW PETER (GB) | 2004-12-23 | — | — | US | disclosed |
| WO-2003026641-A2 | MODULATION OF STAT ACTIVITY | UNIVERSITY OF NOTTINGHAM (GB) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003022828-A1 | USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003004017-A1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259942-A1 | Modulation of stat activity | STAT3, STAT1, STAT4 | FAAH 2550/4885MAPT 4800/4885KMT2A 2237/4885 |
| US-20050014751-A1 | Use of n-acyl homoserine lactones for the treatment of insulitis | HPGDS, CD14, IFNG | FAAH 299/4885MAPT 4663/4885KMT2A 4475/4885 |
| US-20030171371-A1 | Immunosuppressant n-acyles homoserine lactones | MSR1, IL4, SRR | FAAH 358/4885MAPT 4833/4885KMT2A 3356/4885 |
| US-20040198978-A1 | Synergistic compositions of n-acylhomoserine lactones and 4-quinolones | CBR3, CBR1, CNR1 | FAAH 412/4885MAPT 4873/4885KMT2A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.